[Editorial] Emotion-based medicine or evidence-based medicine?
The Lancet Oncology
The UK National Institute for Health and Care Excellence (NICE) is once again under the microscope because of recent recommendations for various cancer drugs. In the past 2 months, just one recommendation out of four has been positive. Nab-paclitaxel for metastatic pancreatic cancer (Sept 8, 2014); trastuzumab emtansine for HER2-positive breast cancer (Aug 7, 2014); and abiraterone for metastatic, hormone-resistant prostate cancer (Aug 14, 2014) have all been rejected on the grounds of insufficient cost-effectiveness.
Original Article: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70498-X/fulltext?rss=yes
No comments:
Post a Comment